New real-world data on the blood thinner Xarelto show positive efficacy in treating patients for the prevention of the recurrence of blood clots, reports Johnson & Johnson’s Janssen Pharmceuticals and Bayer, makers of Xarelto. Data showed that patients with blood clots, or venous thromboembolism (VTE) treated with Xarelto for more than three months had a lower risk of VTE recurrence without an increase in major bleeding compared to patients taking Xarelto for less than three months. Another study based on Janssen’s ongoing Post-Market Safety Surveillance (PMSS) study in VTE showed that major bleeding rates in patients treated with Xarelto for ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.